Skip to main content

Sjogrens

Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx
Dr. John Cush @RheumNow( View Tweet )
Jun 25, 2022
#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 04, 2022
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 03, 2022
Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI
Richard Conway @RichardPAConway( View Tweet )
Jun 03, 2022
New Tool! STAR (#Sjogren’s Tool for Assessing Response) was developed to assess treatment response in primary Sjogren’s and will be validated on 3 datasets #EULAR2022 @rheumnow OP0286 https://t.co/9tgVSWGxEc
TheDaoIndex @KDAO2011( View Tweet )
Jun 03, 2022
Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2
Richard Conway @RichardPAConway( View Tweet )
Jun 02, 2022
#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Jun 01, 2022
#ClinicalPearl Autoantibodies in #Sjogren’s Syndrome include CCP and anticentromere - think of overlaps with #rheumatoid arthritis or lcSSc limited cutaneous systemic sclerosis #scleroderma #CCR22 #CCR2022 ⁦@RheumNow⁩ https://t.co/vrdbv640B5
May 13, 2022
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
cancer, melanoma, metastatic, cell

Increased Cancer Risk with Autoimmune Disorders

Mar 31, 2022

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.



The cohort included 8,120 AID patients from a national tertiary referral

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

Mar 16, 2022

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).



Previously environmental pollutants have been linked to an increased risk of

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

Feb 15, 2022

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.



These recommendations are applicable to patients with gout, vasculitis, systemic

Read Article
ICYMI: Top Tweet in January Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.https://t.co/SLn2qs8En4 https://t.co/nMOUm2C9It
Dr. John Cush @RheumNow( View Tweet )
Feb 06, 2022
ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI
Dr. John Cush @RheumNow( View Tweet )
Jan 15, 2022
Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

Jan 11, 2022

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.



This was a phase II, dose-finding trial, aimed to assess

Read Article
Study of subcutaneous ianalumab in patients with primary Sjögren's syndrome met primary objective, showing dose-related decrease in disease activity (ESSDAI) at week 24: randomised, double-blind, placebo-controlled trial. https://t.co/NqdDWqpX2g https://t.co/PSxSRx28fM
The Lancet @TheLancet( View Tweet )
Jan 11, 2022
121 Sjögren’s pts dx w/ non-Hodgkin's lymphoma - 76% were MALT lymphoma (9% Diffuse Large B Cell, 7% Nodal Marginal Zone Lymphomas). MALT 10-yr survival was 79% MALT. Predictors were Cryoglobulinemia, focus score, ESSDAI at Dx https://t.co/EYsB06DU4s

Dr. John Cush @RheumNow( View Tweet )

Jan 03, 2022
fetus,defect,baby,malformation

Best of 2021: Potential Birth Defects with Hydroxychloroquine

Dec 23, 2021

HCQ is one of the safest meds used in rheumatology, but new claims data suggests a small increase in the risk of malformations associated with first-trimester HCQ use. The March 2021 issue of the American Journal of Obstetrics and Gynecology studied the risk of major congenital malformations

Read Article
Cancer,cells

Certain Cancers Increased with Autoimmune Diseases

Dec 16, 2021

Rheumatologists are well aware that inflammation and immune dysregulation are prime contributors to cancer risk, but do oncologists carry the same impressions? A large study from JAMA Oncology shows that patients with immune-mediated diseases (IMD) have an overall increased risk of cancer,

Read Article
#ACR21 #ACR2021 Sjogrens syndrome with pulmonary involvement guidelines 🚨Thread Alert 👉🏻Screen all patients for pulm inv. irrespective of symtopms ➡️ prevlance of lung involvement can be upto 65% 👉🏻Complete PFT includes ➡️ Spirometry➕ DLCO➕ PuseOximetry https://t.co/prFgQESRyF
EnvisionRheumat @ERheumat( View Tweet )
Nov 09, 2021
#ACR21 #Abstr1908 Potential prognostic biomarker for lymphoma in #sjogren. ISG15 (IFN-I) expression was consistently ⬆️in pts with lymphoma vs none, both in blood and salivary gland biopsy. Work needed re: relation to other markers, ethnicity @RheumNow https://t.co/8VYYEXpXSw https://t.co/ZIkpx5kUfu
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 09, 2021
#Abstr0002 #ACR21 What drives salt in saliva in #sjogren? A study suggested Bcell cytokines mediated the epithelial Na+ Channel disruption. A case for targeting Bcell to improve oral health @RheumNow https://t.co/Bx3kBpOIFX https://t.co/YYnC6UoMJY
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 08, 2021
Knowledge Bowl at #ACR21 ⭐️The first lung fibrosis described in Sjogren's with lung biopsy showing benign polyclonal lymphocytes and plasma cells with a risk for malignant transformation. ➡️Lymphocytic Interstitial Pneumonia @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 08, 2021
Lab work

Infection or Disease Flare: What Tools Can Help Differentiate?

Nov 08, 2021

Differentiation between a flare of disease and infection in patients with autoinflammatory (AI) conditions, where fever is the hallmark, can be extremely difficult. Few studies have evaluated potential differentiators; and having such tools would meet a huge unmet need. 

Read Article
Does concomitant SJS affect tx effectiveness in RA? Abst#0839 suggest yes! ➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores. What's your clinical experience with this? #ACR21 @Rheumnow https://t.co/TIc3raMOSJ
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 07, 2021
×